链接：https://www.abinscience.cn/product/78/43501.html
名称：BDBV VP30 Recombinant Protein (N-His)
货号：VK060012
表达系统：E. coli
Accession号：ACI28625.1
蛋白长度：Gln135-His289
应用：ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
种属：Bundibugyo virus
性质：Recombinant
内毒素水平：Please contact with the lab for this information.
纯度：>90% as determined by SDS-PAGE.
预测分子量：19.84 kDa
状态：Lyophilized
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
产品介绍：Recombinant BDBV VP30, N-His (VK060012) 是艾必赛生物（abinScience）推出的邦迪布焦埃博拉病毒（Bundibugyo ebolavirus, BDBV）重组 VP30 蛋白，N 端带 6×His 标签，大肠杆菌表达，覆盖 Gln135–His289，经 IMAC（Ni 柱）纯化，纯度 >90%（SDS-PAGE），以冻干粉形式保存在 PBS pH 7.4 + 1 mM EDTA + 4% 海藻糖 + 1% 甘露醇 中，重悬后常规 2–8°C，长期 -20 至 -80°C 避反复冻融（≤12 个月）。适用于 ELISA、免疫原、WB 等方法，bioactivity 验证进行中。（RUO，仅限科研/非临床用途）
VP30 是丝状病毒核衣壳复合体的转录激活因子，与 NP、VP35 协同调控病毒基因组转录/复制开关，是埃博拉病毒转录机制研究与抗病毒筛选的关键靶蛋白。BDBV 为 2007 年于乌干达邦迪布焦地区首次分离的埃博拉病毒种，归类丝状病毒科、单股负链 RNA 病毒，病死率约 50%，人际传播同样依赖接触患者/死者血液、体液及污染物；作为仅次于扎伊尔型的致死毒株，其核蛋白（NP/VP30/VP35）重组抗原是 BDBV 血清学检测、疫苗/药物评价中常用的阳性参照与免疫原材料，VK060012 截短表达（19.84 kDa）、His 标签便于纯化与包被，适合搭建 BDBV 相关 assay。
产品购买联系方式：027-87433958/17302791434
邮箱：info@abinscience.com
参考文献：
A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection. PMID: 37290053
Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling. PMID: 34372693
Molecular analysis of the 2012 Bundibugyo virus disease outbreak. PMID: 34467242
Pan-ebolavirus protective therapy by two multifunctional human antibodies. PMID: 34715022
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. PMID: 30629918
Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines. PMID: 42245043
Multivalent mRNA vaccine platform with compatible antigens conferred broad-spectrum protection against orthoebolaviruses' exposure. PMID: 42150061
A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. PMID: 37171813
Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. PMID: 30629917
A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus. PMID: 41839884
Diagnostic performance of RADIONE for diagnosis of BDBV. PMID: 42309094
Nanobody targeting glycan cap confers broad orthoebolavirus neutralization. PMID: 41962742
Bundibugyo virus disease: transmission dynamics, infectiousness and viral persistence. PMID: 42365920
Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System. PMID: 34379503
A Single-Dose Intranasal Combination Panebolavirus Vaccine. PMID: 37469133
Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. PMID: 27489269
Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24. PMID: 37243162
Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway. PMID: 35130104
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines. PMID: 38458540
Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. PMID: 35584193
Nonhuman Primate Models of Ebola Virus Disease. PMID: 28643203
Conserved Filovirus Proteins as Targets of Broad-Spectrum Antivirals. PMID: 41040300
Dual roles of CXCR4 (C-X-C motif chemokine receptor 4) in promoting entry of ebolavirus and targeting excessive glycoprotein for reticulophagic degradation to facilitate viral fitness. PMID: 40223186
Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species. PMID: 42080802
Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin. PMID: 37858466
A Single-Dose Bundibugyo Virus Vaccine Protects Macaques Within 3 Days. PMID: 42367993
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. PMID: 30518655
Resilience and residuals beyond containment - The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study. PMID: 41918761
Contribution of Environment Sample-Based Detection to Ebola Outbreak Management. PMID: 30325435
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development Accelerates. PMID: 42383297
Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. PMID: 30184505
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. PMID: 26806128
Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. PMID: 34093585
Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. PMID: 26819310
The Impact of Diagnostic Delays and Timeliness of Response on Ebola Disease outbreak-level case-fatality Ratios in Uganda (2000-2023): a Rapid Systematic Review and meta-analysis. PMID: 41219638
详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn
【英文】https://www.abinscience.com
武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。
返回顶部
扫一扫关注我们